CM
CSTL icon

Castleark Management’s Castle Biosciences CSTL Stock Holding History

Castleark Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-147,867
Closed -$9.83M – 337
2021
Q3 		$9.83M Sell
147,867
-7,570
-5% -$533K 0.38% 76
2021
Q2 		$11.4M Sell
155,437
-8,170
-5% -$540K 0.38% 64
2021
Q1 		$11.2M Buy
163,607
+15,410
+10% +$1.16M 0.4% 69
2020
Q4 		$9.95M Sell
148,197
-16,901
-10% -$916K 0.37% 63
2020
Q3 		$8.49M Buy
165,098
+17,373
+12% +$773K 0.33% 88
2020
Q2 		$5.57M Buy
+147,725
New +$5.05M 0.24% 115

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Castleark Management's CSTL Position: Q4 2021 in Review

Castleark Management sold out of Castle Biosciences (CSTL) in Q4 2021, closing a stake of 147,867 shares — an estimated $9.83M sold.

Castleark Management first reported a position in CSTL in Q2 2020 and held it in 6 quarters. The position peaked at $11.4M in Q2 2021. 159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

  • Castleark Management reported no remaining Castle Biosciences position as of Q4 2021 after selling out during the quarter.
  • Castleark Management sold 147,867 Castle Biosciences shares in Q4 2021, an estimated $9.83M.
  • Castleark Management first reported a position in Castle Biosciences in Q2 2020 and held it in 6 quarters.
  • Castleark Management's Castle Biosciences position peaked at $11.4M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on Castleark Management's 13F filing for Q4 2021, filed 16 Feb 2022.